89Zr-DFO-REGN3767

DRUG2 trials

Sponsors

Memorial Sloan Kettering Cancer Center, University Medical Center Groningen

Conditions

DLBCLLarge B-cell LymphomaMetastatic Solid Tumor

Early Phase 1

89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)

CompletedNCT04566978

Memorial Sloan Kettering Cancer CenterDLBCL, Large B-cell Lymphoma

Start: 2020-09-11End: 2025-03-21Updated: 2025-04-23

Phase 1

LAG3 PET Imaging in Advanced Solid Tumors

Active, not recruitingNCT04706715

University Medical Center GroningenMetastatic Solid Tumor

Start: 2022-01-18End: 2025-11-30Updated: 2025-05-31

Related Papers

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.

2023-08-075 citations

Abstract 5611: LAG-3 PET imaging in patients with cancer before immune checkpoint inhibitor therapy

Cancer Research2023-04-042 citations

<sup>89</sup>Zr-immuno-PET using the anti-LAG-3 tracer [<sup>89</sup>Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC.

2023-03-0224 citations